A controlled study of danazol for the treatment of karyotypically normal spontaneous premature ovarian failure

James N. Anasti, J N Anasti, L M Kimzey, Lorene M. Kimzey, Ruby Defensor, R A Defensor, B White, Beverly J. White, L M Nelson, Lawrence M. Nelson
Fertility and sterility · 1994 · vol. 62(4) , pp. 726–730 · doi:10.1016/s0015-0282(16)56996-9 · PMID:7926080 · W2419297781
RCT OA: closed CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

This controlled study investigated the efficacy of danazol in treating karyotypically normal spontaneous premature ovarian failure.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine if the immunomodulatory and gonadotropin-suppressing properties of danazol would improve follicle function or ovulation rates in patients with karyotypically normal spontaneous premature ovarian failure. DESIGN: Prospective, double-blind, crossover trial. SETTING: Tertiary care research institution. INTERVENTIONS: Two intervention phases lasting 4 months each: one phase during which patients received a standardized estrogen and progestin replacement regimen and one phase during which each patient received a twice daily 400 mg oral dose of danazol. PATIENTS: Fifty-two patients with karyotypically normal spontaneous premature ovarian failure ranging in age from 21 to 39 years. MAIN OUTCOME MEASURES: We measured serum E2 and P levels weekly during the 2 months after each intervention. We defined a serum E2 > 50 pg/mL (184 pmol/L) as evidence of ovarian follicle function and a P > 3.0 ng/mL (9.5 nmol/L) as evidence for ovulation. RESULTS: Of the 46 patients who completed the study, danazol did not significantly enhance ovarian follicle function or the chance of ovulation. Eight patients ovulated after danazol and four patients ovulated after estrogen and progestin. The power to detect a 30% and a 5% ovulation success rate with therapy was 0.80 and 0.90, respectively. Overall, 30 of 46 women (65%) demonstrated ovarian follicle function and 10 women (21%) ovulated. CONCLUSION: We were unable to demonstrate a statistically significant benefit from the immunomodulatory and gonadotropin-suppressing effects of danazol in patients with karyotypically normal spontaneous premature ovarian failure. These patients often have spontaneous remission. Thus, controlled studies are required to determine the effectiveness of treatments for this condition.

My notes (saved in your browser only)

MeSH descriptors

Danazol Primary Ovarian Insufficiency Adult Cross-Over Studies Danazol Double-Blind Method Estrogen Replacement Therapy Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Karyotyping Luteinizing Hormone Luteinizing Hormone Ovary Ovary Ovary Primary Ovarian Insufficiency Primary Ovarian Insufficiency Prospective Studies

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (29)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-13T18:37:28.025090+00:00
pubmed
last seen: 2026-10-08T21:59:07.256998+00:00
unpaywall
last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0 · commercial use OK